Stock KALV KALVISTA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus KalVista Pharmaceuticals, Inc.

Equities

KALV

US4834971032

Market Closed - Nasdaq
Other stock markets
 16:30:01 2024-05-06 EDT 		5-day change 1st Jan Change
12.14 USD +0.08% Intraday chart for KalVista Pharmaceuticals, Inc. +10.26% -0.90%
04-22 Kalvista Pharmaceuticals, Inc. Appoints William C. Fairey to the Board of Directors CI
04-15 Certain Common Stock of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024. CI

Evolution of the average Target Price on KalVista Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

1efdb9bc06ce4d8352a91d05f4d8d.nIQ9TYuCvRPOgVOSXTbtu-8ozEZOIPrf7KP_8ZmIqbk.xdFFA_3N6USiyALXZWOM-ahBnhQcSI2xu_mLrvXXxdLVyFEcvuTkaY_gAg~3e1b802729d8e5faa5e4445674765c61

Analyst Recommendations on KalVista Pharmaceuticals, Inc.

HC Wainwright Adjusts Price Target on KalVista Pharmaceuticals to $24 From $16, Maintains Buy Rating MT
SVB Securities Adjusts KalVista Pharmaceuticals' Price Target to $20 From $30, Maintains Outperform Rating MT
HC Wainwright Adjusts KalVista Pharmaceuticals' Price Target to $16 From $48, Reiterates Buy Rating MT
SVB Securities Adjusts Price Target on KalVista Pharmaceuticals to $30 From $45, Keeps Outperform Rating MT
Needham Lowers KalVista Pharmaceuticals Price Target to $24 From $38, Maintains Buy Rating MT
SVB Securities Adjusts KalVista Pharmaceuticals' Price Target to $45 from $51, Keeps Outperform Rating MT
Needham Adjusts Price Target on KalVista Pharmaceuticals to $38 From $42, Reiterates Buy Rating MT
Stifel Nicolaus Adjusts KalVista Pharmaceuticals' Price Target to $32 From $54, Maintains Buy Rating MT
Needham Adjusts KalVista Pharmaceuticals' Price Target to $42 from $48, Keeps Buy Rating MT
Cantor Fitzgerald Lowers Price Target for KalVista Pharmaceuticals to $33 From $49, Maintains Overweight Rating MT
Needham Adjusts KalVista Pharmaceuticals' Price Target to $48 from $50, Keeps Buy Rating MT
KALVISTA PHARMACEUTICALS : Roth Capital Adjusts Price Target on KalVista Pharmaceuticals to $55 From $30, Maintains Buy Rating MT
KALVISTA PHARMACEUTICALS : SVB Leerink Adjusts Price Target on KalVista Pharmaceuticals to $51 From $39, Keeps Outperform Rating MT
KALVISTA PHARMACEUTICALS : HC Wainwright Adjusts Price Target on KalVista Pharmaceuticals to $48 From $30, Maintains Buy Rating MT
KALVISTA PHARMACEUTICALS : Stifel Adjusts Price Target on KalVista Pharmaceuticals to $54 From $30, Reiterates Buy Rating MT
KALVISTA PHARMACEUTICALS : Needham Adjusts KalVista Pharmaceuticals' Price Target to $32 From $25, Keeps at Buy MT
KALVISTA PHARMACEUTICALS : SVB Leerink Adjusts KalVista Pharmaceuticals' Price Target to $39 From $28, Keeps at Outperform MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
12.13 USD
Average target price
29.8 USD
Spread / Average Target
+145.67%
High Price Target
39 USD
Spread / Highest target
+221.52%
Low Price Target
20 USD
Spread / Lowest Target
+64.88%

Consensus detail

Consensus revision (last 18 months)

Analysts covering KalVista Pharmaceuticals, Inc.

HC Wainwright
SVB Securities LLC
Needham & Co.
Stifel Nicolaus
Cantor Fitzgerald
Roth Capital Partners
SVB Leerink

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. KALV Stock
  4. Consensus KalVista Pharmaceuticals, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW